Venture Capital
Stemirna Therapeutics, a Chinese biotech start-up focusing on RNA technology-based drug development, has raised nearly RMB100 million (US$14.16 million) in a serious A round of financing. Chinese venture capital firm Shanghai Zhangjiang Torch Venture Capital, investment firm Longmen Capital, Jiuyou Capital, and Fanghua Investment all poured money into the investment. Returning investor Longpan Investment also […] Chinese Biotech Start-Up Stemirna Therapeutics Raises $14M Series A Round comes originally from China Money Network. All Rights Reserved.